Coronavirus Outbreak: First Human Trial Started In USA This Week
The coronavirus outbreak has scared the whole world with the manner in which it is targeting the lives of human. The virus that is said to be originated from the Wuhan province of China is now present in almost every country of the world. It is being said that the virus COVID-19 originated from the seafood market of Wuhan where some exotic animals were being sold illegally. Due to the coronavirus outbreak more than 11,000 people have lost their lives while more than 270000 have been infected with it globally.
Here are some important points regarding the COVID-19 and what makes it so lethal:
1 What is COVID-19?
COVID-19 or coronavirus is zoonotic which means that it has been transferred in humans from animals. It is contagious and people affected with this virus should be kept in isolation otherwise many other people could also get affected. It can cause diseases starting from common cold to severe respiratory problems.
2Symptoms of infection
Infected person will show the symptoms of common cold, cough, fever, breathing problem and if he is not treated on time, he may suffer from pneumonia, severe acute respiratory syndrome which will adversely affect lungs and kidney and person may lose his life as well. People should cover their mouth and nose while coughing and sneezing so that infection doesn’t gets transmit into others.
3What makes it so lethal?
The whole world is afraid of coronavirus because we don’t have any vaccine or medicine which can cure it. At the moment human beings can only do one thing and that is taking precautions. Staying indoors is the best way to remain safe, avoid places of mass gathering and focus on personal hygiene.
The good news is that the work of developing the vaccine has started and the first human trial also started this week in USA. This trial is being conducted at Kaiser Permanente Washington Health Research Institute (KPWHRI), Seattle and information regarding this was given by USA President Donald Trump to the media persons on Monday.
5Who is funding the trial?
This trial is being funded by the National Institute of Allergy and Infectious Diseases (NIAID) which comes under the National Institutes of Health (NIH). 45 volunteers (males and non-pregnant females) of age ranging between 18-55 yrs will take part in this trial for the time period of six weeks.